The ethics of CYP2D6 testing for patients considering tamoxifen

被引：9

作者：

Hartman, Anne-Renee ^{[1
]}

Helft, Paul ^{[1
]}

机构：

[1] Indiana Univ, Div Hematol & Oncol, Indianapolis, IN 46202 USA

来源：

BREAST CANCER RESEARCH | 2007年 / 9卷 / 02期

关键词：

Tamoxifen; Poor Metabolizers; Adjuvant Hormonal Therapy; Adjuvant Tamoxifen; Perimenopausal Woman;

D O I：

10.1186/bcr1663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.

引用

页数：2

共 8 条

[1] The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen [J].

Goetz, Matthew P. ;

Knox, Stacey K. ;

Suman, Vera J. ;

Rae, James M. ;

Safgren, Stephanie L. ;

Ames, Matthew M. ;

Visscher, Daniel W. ;

Reynolds, Carol ;

Couch, Fergus J. ;

Lingle, Wilma L. ;

Weinshilboum, Richard M. ;

Fritcher, Emily G. Barr ;

Nibbe, Andrea M. ;

Desta, Zeruesenay ;

Nguyen, Anne ;

Flockhart, David A. ;

Perez, Edith A. ;

Ingle, James N. .

BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) :113-121

[2]

GOETZ MP, 2004, BREAST CANC RES TR S, V1

[3]

Grabinski JL, 2006, J CLIN ONCOL, V24, p4S

[4] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment [J].

Jin, Y ;

Desta, Z ;

Stearns, V ;

Ward, B ;

Ho, H ;

Lee, KH ;

Skaar, T ;

Storniolo, AM ;

Li, L ;

Araba, A ;

Blanchard, R ;

Nguyen, A ;

Ullmer, L ;

Hayden, J ;

Lemler, S ;

Weinshilboum, RM ;

Rae, JM ;

Hayes, DF ;

Flockhart, DA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :30-39

[5]

National Comprehensive Cancer Network, CLIN PRACT GUID ONC

[6]

*SOFT, PHAS 3 TRIAL EV ROL

[7] Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine [J].

Stearns, V ;

Johnson, MD ;

Rae, JM ;

Morocho, A ;

Novielli, A ;

Bhargava, P ;

Hayes, DF ;

Desta, Z ;

Flockhart, DA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (23) :1758-1764

[8] American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 [J].

Winer, EP ;

Hudis, C ;

Burstein, HJ ;

Wolff, AC ;

Pritchard, KI ;

Ingle, JN ;

Chlebowski, RT ;

Gelber, R ;

Edge, SB ;

Gralow, J ;

Cobleigh, MA ;

Mamounas, EP ;

Goldstein, LJ ;

Whelan, TJ ;

Powles, TJ ;

Bryant, J ;

Perkins, C ;

Perotti, J ;

Braun, S ;

Langer, AS ;

Browman, GP ;

Somerfield, MR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :619-629

← 1 →